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ABSTRACT
Saccharomyces cerevisiae HMO1, a high mobility
group B (HMGB) protein, associates with the rRNA
locus and with the promoters of many ribosomal
protein genes (RPGs). Here, the Sos recruitment
system was used to show that HMO1 interacts with
TBP and the N-terminal domain (TAND) of TAF1,
which are integral components of TFIID. Biochem-
ical studies revealed that HMO1 copurifies with
TFIID and directly interacts with TBP but not with
TAND. Deletion of HMO1 (Dhmo1) causes a severe
cold-sensitive growth defect and decreases tran-
scription of some TAND-dependent genes. Dhmo1
also affects TFIID occupancy at some RPG promo-
ters in a promoter-specific manner. Interestingly,
over-expression of HMO1 delays colony formation of
taf1 mutants lacking TAND (taf1DTAND), but not of
the wild-type strain, indicating a functional link
between HMO1 and TAND. Furthermore, Dhmo1
exhibits synthetic growth defects in some spt15
(TBP) and toa1 (TFIIA) mutants while it rescues
growth defects of some sua7 (TFIIB) mutants.
Importantly, Dhmo1 causes an upstream shift in
transcriptional start sites of RPS5, RPS16A, RPL23B,
RPL27B and RPL32, but not of RPS31, RPL10, TEF2
and ADH1, indicating that HMO1 may participate in
start site selection of a subset of class II genes
presumably via its interaction with TFIID.
INTRODUCTION
Transcriptional initiation of protein-coding (class II) genes
by RNA polymerase II (Pol II) involves a set of general
transcription factors (GTFs: TFIIA, TFIIB, TFIID,
TFIIE, TFIIF and TFIIH), as well as other cofactors
including mediator, histone-modifying enzymes and
ATP-dependent chromatin remodeling complexes (1–3).
Upon transcriptional activation, gene-speciﬁc activators
recruit the active forms of these components to the
promoter region surrounding the transcriptional initiation
site of target genes (4,5). Despite considerable investiga-
tion, details of the molecular mechanisms underlying
transcriptional activation remain unclear. TFIID, which
is composed of the TATA box-binding protein (TBP) and
14 TBP-associated factors (TAFs), not only recognizes a
set of core promoter elements, but also serves as one of
the most important targets for activators (6). The TAF1
N-terminal domain, TAND, binds to the concave and
convex surfaces of TBP, thereby inhibiting TBP binding to
the TATA element (7). The loading of TBP onto the
promoter is a key regulatory step for activation (8–10) and,
thus, we proposed that activators reverse the TAND–TBP
interaction, enabling formation of a productive TFIIA–
TBP–TATA complex (11).
High mobility group B (HMGB) proteins constitute a
subgroup of non-histone HMG proteins in eukaryotic
chromatin. They contain one or more HMG box domains
(12,13) that are distinctive DNA-binding motifs, in which
the global fold is well conserved and comprises three
helices arranged in an L-shape (14,15). HMGB proteins
are involved in diverse biological processes, including
transcription, recombination and DNA repair, by facil-
itating assembly of nucleoprotein complexes that are
required for these processes (16–18). Notably, some yeast
and human HMGB proteins are transcriptional coactiva-
tors that stabilize the TBP/TFIID–TFIIA–promoter
complex (19,20).
Saccharomyces cerevisiae expresses seven HMGB pro-
teins, HMO1, HMO2 (also called NHP10), NHP6A,
NHP6B, ABF2, ROX1 and IXR1. Among these proteins,
only HMO1 is involved in both RNA polymerase I
(Pol I)- and Pol II-mediated transcription (21–23). HMO1
binds to promoters of most ribosomal protein genes
(RPGs, 97 of 138) as well as promoters of 386 non-RP
target loci over the entire genome (22,23). Our recent work
also revealed that 138 RPGs can be classiﬁed into
13 distinct groups based on HMO1-abundance at the
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RAP1 binding to the promoter (23). Both FHL1 and/or
RAP1 are key regulators of RPG transcription (24–30).
Interestingly, FHL1 binds to most of the HMO1-enriched
and transcriptionally HMO1-dependent RPG promoters
in an HMO1-dependent manner, whereas it binds to
HMO1-limited RPG promoters in an HMO1-independent
manner (23).
This study shows that HMO1 interacts physically
and genetically with TAND and TBP/TFIID. Genetic
analyses also indicate a close relationship between the
functions of HMO1 and TAND, TBP, TFIIB and TFIIA.
Surprisingly, hmo1 rescues growth defects of some sua7
(TFIIB) mutants and causes an upstream shift in
transcriptional start sites of some genes, e.g. RPS5,
RPS16A, RPL23B, RPL27B and RPL32, but not of
others, e.g. RPS31, RPL10, TEF2 and ADH1. Similarly,
tfg1/tfg2 (TFIIF) (31–33) and rpb2/rpb9 (Pol II) (34–37)
mutations rescue the growth defect of some sua7 mutants,
and also shift the start site of ADH1 upstream. Thus, it is
likely that HMO1 participates in the start site selection of
a subset of class II genes by a mechanism that diﬀers from
that of TFIIF and Pol II.
MATERIALS AND METHODS
Yeaststrains
Standard techniques were used for growth and transfor-
mation of yeast (38). The yeast strains used in this study
are listed in Supplementary Table 1. The spt15 strain
(YTK271) has been described previously (39). YTK271,
YTK8264, YTK8270, YTK8166, YTK8269 and YTK
8273 were used as parental strains for exchange of
plasmids encoding wild-type TBP, TFIIB or TFIIA with
plasmids encoding mutant proteins. YKK74 was gener-
ated as described previously (23).
Targeted disruption of HMO1 was performed by PCR-
based gene deletion (40) using the primers TK4022 and
TK4023. The oligonucleotides used in this study are
listed in Supplementary Table 2. HMO1 disrupted
strains YTK8468, YTK8166, YTK8269 and YTK8273
were generated from Y13.2, YTK271, YTK8264 and
YTK8270, respectively, using HIS3 as the selectable
marker. Using kanMX as the selectable marker, targeted
disruptions of SUA7 (primers TK7770-TK6225) and
TOA1 (primers TK7768-TK5565) were performed in the
H2451 strain (41) to generate the YTK8264 and YTK8270
strains, respectively.
A number of strains were generated using a plasmid
shuﬄe technique, whereby, for example, pYN1/TAF1
(URA3 marker) was replaced with a TRP1-marked plas-
mid, by growing transformants on 5-ﬂuoroorotic acid
(5-FOA)-containing plates. Using the plasmids pM2715/
TAF1, pM2722/taf12-86 or pM2727/taf12-186, the
YTK8472, YTK8473 and YTK8474 strains, respectively,
were generated from YTK8468 and the YTK8469, YTK
8470 and YTK8471 strains, respectively, were generated
from Y13.2. YKK237, YKK238, YKK241 and YKK247
were generated from Y22.1 (41) using the pM1169/TAF1,
pM977/taf141-73, pM1002/taf18-42 or pM1001/
taf110-73 plasmids, respectively.
Construction of plasmidsfor theSos recruitment system
A 0.65kb fragment containing TAND (1–208 aa) was
ampliﬁed by PCR using the TK2697 and TK2698 primers,
and then ligated into a blunt-ended BamHI site in
pSos (Stratagene), generating the bait plasmid pM2718.
A 0.89kb fragment containing the GAL1 promoter, a
myristylation signal and the CYC1 terminator of pMyr
(Stratagene) was ampliﬁed by PCR using the TK3528 and
TK3529 primers, and ligated into the PvuII site of pRS426
(42), forming the pM2721 vector. As prey, yeast cDNA
was prepared using a cDNA synthesis kit (Stratagene),
digested with EcoRI-XhoI and then ligated into a
similarly digested pM2721.
DNA fragments (0.73kb) encoding TBP were ampliﬁed
by PCR using the TK4348-TK936 primers, then digested
and ligated into the BamHI-SalI sites of pSos, forming
pM2875 or ampliﬁed using the TK21-TK936 primers,
digested and ligated into the EcoRI-SalI sites of pMyr,
forming pM2719. A 0.74kb fragment encoding HMO1
was ampliﬁed by PCR using the TK3807 and TK3808
primers, digested, and ligated into the EcoRI-XhoI site
of pM2721, forming pM2754.
Construction of plasmidsfor theGST pulldown assay
The plasmid encoding His-TBP (pM1578) has been
described previously (39). A 0.73kb fragment encoding
TBP was ampliﬁed by PCR using the TK1 and TK2
primers, digested, and ligated into the BamHI-EcoRI sites
of pGEX-2T (GE Healthcare Biosciences), generating
pM4673 (encoding GST-TBP). Similarly, the expression
plasmids pM2773 (GST-TAND; 6–208 aa) and pM2823
(GST-HMO1, 1–246 aa) were constructed by ligating a
0.6kb BamHI (internal)-NotI fragment from pM2718 and
a 0.74kb EcoRI-XhoI fragment from pM2754, respec-
tively, into pGEX-6P-1 (GE Healthcare Biosciences). The
expression plasmid pM5214 (His-HMO1) was constructed
by ligating a 0.74kb EcoRI-XhoI fragment from pM2754
into pCold 1 (TaKaRa).
Construction of plasmidsfor geneticstudies
TAF1 plasmids. pM1169 (TAF1/pRS314), pM1001
(taf110-73/pRS314), pM1002 (taf18-42/pRS314),
pM977 (taf141-73/pRS314), pM1689 (taf12-86/
pRS314) and pM1657(taf12-186/pRS314) have been
described previously (43,44). The NcoI-NruI fragment of
pM1169 was replaced with the NcoI-EcoRV fragment of
pBS1479, generating pM2711. A 0.82kb fragment was
ampliﬁed by PCR from pM1169 using the TK120 and
TK3516 primers, digested and ligated into the NcoI site
of pM2711, generating pM2715 (TAF1-TAP/pRS314).
The 1.6kb BlnI-PstI fragments of pM1689 and pM1657
were replaced with the BlnI-PstI fragment of pM2715,
generating pM2722 and pM2727, respectively.
HMO1 plasmids. pM2897 was constructed by ligating
a 0.74kb EcoRI-XhoI fragment from pM2754 into
similarly digested p414-TEF (45). SacI-NaeI fragments
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(1.5kb) and p414-GPD (1.3kb) were ligated into simi-
larly digested pRS315 (46), generating pM2949 (TEF1
promoter-driven HMO1/pRS315), pM2950 (TDH3 pro-
moter-driven HMO1/pRS315), pM2956 (TDH3
promoter-driven VTC1/pRS315) and pM2959 (TDH3
promoter only/pRS315), respectively. pM2899 was con-
structed by ligating a 0.74kb EcoRI-XhoI fragment from
pM2754 into similarly digested p414-GPD (45). A 0.45kb
fragment encoding VTC1 was ampliﬁed by PCR using the
TK2340 and TK2341 primers, digested and ligated into
the BamHI-PstI sites of p414-GPD, generating pM2933.
TBP, TFIIB and TFIIA plasmids. Plasmids expressing
wild-type TBP or its mutants in yeast cells have been
described previously (39). In this study, the following
plasmids were generated to express TFIIB, TFIIA and
their mutants. A 3.0kb fragment containing SUA7 was
ampliﬁed from genomic DNA by PCR using the TK5948
and TK5949 primers, digested and ligated into the XbaI-
XhoI sites of pRS316 and pRS315, generating pM4326
and pM5283, respectively. pM5283 was subjected to site-
speciﬁc mutagenesis to generate sua7 alleles. The TK7848,
TK7849, TK7850, TK7851, TK7852 and TK7853 primers
were used to generate the pM5287 (E62K), pM5288
(R78C), pM5289 (K190E), pM5290 (K201E), pM5291
(S53P) and pM5292 (G247V) plasmids, respectively.
A 1.9kb fragment containing TOA1 was ampliﬁed from
genomic DNA by PCR using the TK1518 and TK1519
primers, digested and ligated into the BamHI site of
pRS316 and pRS315, generating pM5281 and pM5276,
respectively. Subsequently, pM5276 was subjected to site-
speciﬁc mutagenesis to generate toa1 alleles. The TK7845,
TK7846, TK7847, TK7856 and TK7857 primers were
used to generate the pM5293 (K255A, R257A, K259A),
pM5294 (S220A, S225A, S232A), pM5295 (W285A),
pM5296 (217–227) and pM5297 (55–215/+GGSGG
linker) plasmids, respectively.
A screen forTAND-interacting proteins using theSos
recruitment system
The Sos recruitment system (The CytoTrap
TM Two-
Hybrid System, Stratagene) (47) was used to identify
factor(s) that could interact with TAND or TAF1.
pM2718 (pSos-TAND) was used as bait to screen a yeast
cDNA library constructed in pM2721. Saccharomyces
cerevisiae cdc25H (Supplementary Table 1) was
co-transformed with pM2718 and the pM2721-based
cDNA library, and then plated onto synthetic medium
containing 2% glucose. Colonies grown at 258C were
replica-plated onto synthetic medium containing 2%
glucose, or 2% galactose and 1% raﬃnose. Colonies that
grew on galactose-containing medium at 378C were
checked by PCR to exclude suppressor genes for cdc25
(e.g. CDC25, RAS1, RAS2, SDC25, CYR1, TPK1, TPK2
and TPK3), which are frequently isolated as false positives.
The candidate plasmids were re-transformed into
S. cerevisiae cdc25H with pSos (empty plasmid) or
pM2718, to conﬁrm TAND dependency. The remaining
candidates were sequenced in order to identify proteins
that interacted with TAND.
Proteinexpression andthe GST pulldown assays
His-TBP was expressed in Escherichia coli BL21(DE3)
(Novagen), as described previously (48). His-HMO1
was expressed in E. coli XL1-Blue (Stratagene).
Cells were induced with 0.5mM isopropyl-1-thio-b-D-
galactopyranoside (IPTG) and incubated for 24h at
158C in 50ml of LB broth. GST, GST-tagged TAND
(6–208 aa), GST-tagged HMO1 and GST-tagged TBP
were expressed in E. coli XL1-Blue. Cells were induced
with 0.4mM IPTG and incubated for 3h at 378C (GST,
GST-TAND, GST-HMO1) or at 308C (GST-TBP) in
50ml of LB broth. Cultures were harvested and
pellets resuspended in 500ml of 0.06M KCl/Buﬀer PB
[20mM HEPES–KOH pH 7.9, 0.5mM EDTA, 6mM
MgCl2, 0.1% Nonidet P-40, 20% (v/v) glycerol, 7mM
2-mercaptoethanol and 1mM phenylmethylsulfonyl ﬂuo-
ride (PMSF)]. Following sonication, lysates were clariﬁed
by centrifugation and the supernatants subjected to GST
pulldown assays without further puriﬁcation.
To study the interactions between TAND (6–208 aa),
TBP and HMO1, a bacterial lysate containing His-HMO1
or His-TBP was mixed with one containing GST-TAND,
GST-TBP, GST-HMO1 or GST, in 500ml of 0.1M KCl/
Buﬀer PB, and then incubated at 48C for 120min.
Following addition of 10ml glutathione-Sepharose
TM 4B
(GE Healthcare Biosciences), the incubation was contin-
ued for a further 120min, at which time the beads were
washed three times with 1ml 0.1M KCl/Buﬀer PB. Beads
were boiled in SDS sample buﬀer to elute bound protein,
and the eluates were separated using 10% SDS–PAGE,
followed by immunoblotting with polyclonal anti-HMO1
and anti-TBP antibodies.
TAPpurification
TAP-tagged HMO1 was puriﬁed as described previously
(49) with minor modiﬁcations. A detailed protocol is
available upon request.
Immunoblot analyses
Immunoblotting and preparation of polyclonal antibodies
directed against TAF1, TAF11 and TBP have been
described previously (7,50,51). Polyclonal antibodies
directed against HMO1 (aa 1–246) were raised in rabbits
using gel-puriﬁed His-HMO1 expressed in E. coli.
Chromatin immunoprecipitation (ChIP) analyses
ChIP analysis was conducted according to the Hahn labo-
ratory protocol (http://www.fhcrc.org/science/labs/hahn/
methods/mol_bio_meth/hahnlab_ChIP_method.html),
with minor modiﬁcations. A detailed protocol is available
upon request.
PCR ampliﬁcation conditions were: 948C for 1.5min;
27 cycles of 948C for 15s, 558C for 30s and 728C for 30s
and a ﬁnal extension at 728C for 7min. PCR products
were separated using 5% non-denaturing PAGE and
stained with SYBR Green I (Invitrogen). Each band was
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Film), and the ratio of IP/input was calculated. The
PCR primer pairs used to amplify the following genes
were: RPS5, TK8935/TK9382; RPS31, TK4692/TK4625;
RPL10, TK5031/TK5032; RPL3, TK5035/TK5036;
RPL23B, TK8993/TK8994; RPL27B, TK8997/TK8998;
RPL32, TK8449/TK8450 and the transcribed region of
POL1 (27) (asterisk), TK3506/TK3507.
Northern blot analyses
Northern blot analyses of several endogenous genes were
performed as described previously (50). For detection of
ACT1, RPS5, RPL3, RPS31, RPL10, RPL32, HIS4,
PHO84, PHO12 and GAL1, DNA fragments were
ampliﬁed by PCR from yeast genomic DNA, puriﬁed,
and
32P-labeled using random priming. The PCR primers
used for ACT1, RPS5, RPL3, RPS31, RPL10, HIS4,
PHO84 and PHO12 were described previously (23,43,50).
Other primer pairs used were: RPL32, TK4446/TK4447;
GAL1, TK253/TK254.
RPL23B, RPL27B and 25S rRNA were also detected
by northern blot analysis. The probes were generated
by 50-end labeling gene-speciﬁc oligonucleotides with
[
32P]ATP using the T4 polynucleotide kinase as described
previously (23).
Primerextension analyses
Transcription start sites were mapped by primer extension
analysis as described previously (52). Extension reactions
were conducted using M-MLV reverse transcriptase
(TaKaRa) and [g-
32P]ATP-labeled oligonucleotide pri-
mers. All primers were used both as a primer to generate
the DNA sequencing ladder and for primer extension
reactions. The primers used were: TK3212 (RPS5),
TK3214 (ADH1), TK5414 (RPL10), TK7981 (TEF2),
TK9588 (RPL32), TK9430 (RPS31), TK9589 (RPL27B),
TK9590 (RPL23B) and TK9591 (RPS16A). The cDNA
products were analyzed on a 6.5% polyacrylamide DNA
sequencing gel. Gels were exposed to imaging plates
(BAS2500, Fuji Film) for quantitation and scanning of
electrophoretic images.
RESULTS
HMO1 interacts withTFIID
In this study, the Sos recruitment system (SRS) (47) was
used to screen for novel proteins that bind to TAND. The
Sos system was chosen because it does not depend on
transcription, whereas the standard yeast two-hybrid
system does (11,53). Temperature-sensitive S. cerevisiae
cdc25H carrying pSos-TAND (1–208 aa) was transformed
with the modiﬁed pMyr library. After excluding revertants
and transformants carrying CDC25 or cdc25 suppressor
genes, 75 independent clones expressing Myr-tagged
fusion proteins were identiﬁed for further analysis. These
75 clones included 15 clones carrying the entire HMO1
coding region and expressing the HMO1 protein. Because
the cDNA library was generated using an oligo (dT)
primer and all 15 clones were full length, the N-terminal
segment of HMO1 may be critical for interactions with
TAND.
The interaction between HMO1 and TAND appears to
be speciﬁc, because co-transformation with pMyr-HMO1
and pSos-TAND rescues the growth defect of S. cerevisiae
cdc25H at 378C, while co-transformation with pMyr-
HMO1 and pSos (Figure 1A) or pSos-TAF1 (354–817 aa;
data not shown) does not. Saccharomyces cerevisiae
cdc25H is also viable at 378C in the presence of pMyr-
HMO1 and pSos-TBP (Figure 1A), suggesting that
HMO1 interacts with TBP. In this assay, the strength
of the interaction between HMO1 and TAND/TBP is
indistinguishable from that of the well-characterized
interaction between TAND and TBP (Figure 1A).
Direct binding between HMO1 and TBP was demon-
strated using recombinant proteins in GST pulldown
assays (Figure 1B, lanes 4 and 8). Using this method,
there was no evidence of direct interaction between
HMO1 and TAND (Figure 1B, lane 3), suggesting that
HMO1 interacts indirectly with TAND. This is consistent
with previous studies showing that HMO1 interacts with
TAF11 (54) and TAF13 (55,56). We also examined
whether HMO1 co-puriﬁes with TFIID. A small amount
of TAF1 ( 0.01%), TAF11 ( 0.01%) and TBP
(<0.001%) were recovered with HMO1-TAP puriﬁed
from cell extracts (Figure 1C). These results suggest that
HMO1 regulates transcription of class II genes via an
interaction with TFIID.
Genetic interaction between HMO1 and TAND
Because biochemical studies indicate that HMO1 does not
interact directly with TAND (Figure 1), we examined
whether there is a genetic interaction between these two
factors. On rich medium, we compared the growth
properties of wild-type, single (hmo1, taf1TAND)
and double (hmo1 taf1TAND) deletion mutants
(Figure 2A). Previous studies demonstrated that hmo1
strains exhibit slower growth rates than wild-type strains
over a wide range of temperatures (21,57). In contrast, our
hmo1 strain demonstrated a cold-sensitive growth
phenotype (Figure 2A), presumably due to its speciﬁc
genetic background. A slight (but reproducible) decrease
in growth rate was observed when hmo1 was combined
with taf1TAND [i.e. TAND1+2 (2–86) or
TAND1+2+3 (2–186)] (Figure 2A).
When an HMO1 expression plasmid was transfected
into wild-type and taf1TAND strains, the number of
transformants appeared to be signiﬁcantly lower in
taf1TAND (10–73 aa) than in the wild-type strain
(Figure 2B), due to delayed rates of colony formation in
the former strain. This strain-speciﬁc toxicity was also
HMO1-speciﬁc, because it was not observed with empty
vector (
 ), or with a plasmid overexpressing an unrelated
protein (VTC1). HMO1 was also overexpressed in wild-
type and taf1TAND mutant strains [TAND1 (8–42 aa),
TAND2 (41–73 aa) or both (10–73 aa)] from the TEF1
and TDH3 promoters. The results conﬁrmed that HMO1
overexpression is toxic to cells that are deﬁcient in
TAND1 (Figure 2C). One interpretation of these data is
that HMO1 and TAND1 perform antagonistic roles in
1346 Nucleic Acids Research, 2008, Vol. 36, No. 4regulating TBP. These genetic data support the hypothesis
that HMO1 is involved in transcription of class II genes
via its interaction with TBP/TAND1/TFIID.
The effect of"hmo1 onTFIID-dependent transcription
To test the hypothesis that HMO1 plays a role in
TFIID-dependent transcription, the expression of several
TAND-dependent genes was examined in wild-type, and
in single (hmo1, taf1TAND) or double (hmo1
taf1TAND) deletion mutants cultured at 258C, 308Co r
358C (Figure 3A). As described previously (21), the
steady-state levels of 25S rRNA were lower in the
hmo1 strain at 258C and 308C than in the wild-type
strain (compare lanes 1 and 4). Expression of PHO84,
PHO12, HIS4 and RPS5 were also HMO1-dependent at
258C, 308C and 358C (compare lanes 1 and 4). In contrast,
expression of ACT1 was relatively HMO1-independent,
decreasing signiﬁcantly only in the hmo1 taf1TAND
strains at 258C (compare lanes 2, 3 and lanes 5, 6).
Furthermore, expression of PHO84 was restored in
hmo1 taf1TAND strains at 358C (lanes 5 and 6,
percentages are indicated in the histogram). The results
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Figure 1. HMO1 interacts with components of TFIID. (A) HMO1
interacts with TAND and TBP in the Sos recruitment system.
Saccharomyces cerevisiae cdc25H was transformed with the indicated
combinations of plasmids and grown on appropriately supplemented
2% galactose and 1% raﬃnose minimal medium at 258C (left panel)
or 378C (right panel) for 5 days. Note the revertant colonies (false
positives) that did not grow uniformly in inoculated areas. (B) HMO1
binds TBP, but not TAND. GST pulldown assays were performed
by incubating HMO1 (200pmol in lanes 2–4) or TBP (40pmol in lanes
6–8) with GST-TAND (20pmol in lanes 3 and 7), GST-TBP (20pmol
in lane 4), GST-HMO1 (25pmol in lane 8) and GST (60pmol in lanes 2
and 6). Aliquots of 4% of the total input of HMO1 and TBP are
shown in lanes 1 and 5, respectively. Proteins were separated by 10%
SDS–PAGE and visualized by immunoblotting using antibodies
speciﬁc for the proteins indicated. (C) HMO1 co-puriﬁes with TFIID.
Cell lysates prepared from strains expressing TAP-tagged or un-tagged
HMO1 were puriﬁed as described previously (49) with minor modiﬁ-
cations. Puriﬁed fractions containing TAP-tagged (lane 3) or un-tagged
(lane 2) HMO1 were separated by 7% (TAF1), 10% (TAF11) or
12% (HMO1, TBP) SDS–PAGE and visualized by immunoblotting
using antibodies against the proteins indicated at the left. TAP-tagged
lysates (0.01% of input) are shown in lane 1.
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Figure 2. Genetic interaction between HMO1 and TAND. (A) Eﬀect of
hmo1 and taf1TAND on growth. Strains carrying a combination of
HMO1 or hmo1 and TAF1, taf1TAND (2–86 aa) or taf1TAND
(2–186 aa), as indicated at the left, were spotted onto YPD plates at
three dilutions and grown at 258C, 308Co r3 5 8C for 3 days. (B) The
eﬀect of HMO1 overexpression on growth. Strains carrying TAF1 or
taf1TAND (10–73 aa) were transformed with pM2950 or pM2956 to
overexpress HMO1 or VTC1, respectively, or with empty plasmid
(pM2959, asterisk, negative control). A region of each plate containing
transformants cultured at 308C for 2.5 days is shown. (C) TAND1 or
TAND2 are required to reduce the toxicity of HMO1 overexpression.
As shown in B, strains carrying TAF1, taf1TAND (8–42 aa),
taf1TAND (41–73 aa) or taf1TAND (10–73 aa) were transformed
with ﬁxed amounts (100ng) of empty plasmid ( ) or plasmid
overexpressing HMO1 (pM2949 and pM2950) from the TEF1 or
TDH3 promoters, respectively. Following incubation at 308C for
2.5 days, the number of transformants were counted.
Nucleic Acids Research, 2008, Vol. 36, No. 4 1347are consistent with the hypothesis that HMO1 and TAND
play antagonistic roles in PHO84 transcription. A similar,
but weaker eﬀect was observed for PHO12.
The role of HMO1 in transcription of the inducible
GAL1 gene was also investigated. Here, expression was
measured as a function of time after shift from raﬃnose to
galactose-containing medium in wild-type, and in single
(hmo1, taf1TAND) or double (hmo1 taf1TAND)
deletion mutant strains (Figure 3B). Deﬁciency in HMO1
(hmo1) caused a decrease (or delay) in expression of
GAL1. Deﬁciency in TAND had a similar but more severe
eﬀect, and the eﬀects of these two mutations were additive.
These results indicate that HMO1 and TAND function
together in GAL1 transcription. Signiﬁcantly, mutations
in HMO1 and TAND also had additive eﬀects on
transcription of HIS4 and RPS5 (Figure 3A).
Collectively, these data indicate that HMO1 and TAND
may regulate transcription of distinct subsets of TFIID-
dependent genes in antagonistic or cooperative manners.
The effects of "hmo1and/or taf1"TAND on TFIID
occupancy at severalRPG promoters
Recent studies have shown that HMO1 binds to many
RPG promoters (22,23). We have proposed that 138
RPGs can be classiﬁed into 13 distinct groups based on
HMO1-abundance at their promoters and the HMO1-
dependence of FHL1 and/or RAP1 binding to the
promoters (23). For instance, HMO1 is abundant at
promoters of RPS5, RPL23B, RPL27B and RPL32, but
not RPS31, RPL3 and RPL10 (23). FHL1 binds to the
former group in an HMO1-dependent manner, whereas it
binds to the latter group in an HMO1-independent
manner (23). Intriguingly, however, HMO1-dependency
of transcription of these RPGs does not correlate with
HMO1 binding or HMO1-dependent recruitment of
FHL1 (Figure 4B) (23). Thus, we examined whether
TFIID occupancy at these promoters is correlated with
the HMO1-dependence of transcription. For this purpose,
chromatin immunoprecipitation (ChIP) analyses were
conducted in wild-type, and in single (hmo1,
taf1TAND) or double (hmo1 taf1TAND) deletion
mutants expressing TAP-tagged TAF1 or TAF1TAND
that were cultured at 258C in rich medium (Figure 4A).
The results demonstrate that TFIID occupancy is
greater at RPS5, RPS31 and RPL10 than at RPL3,
RPL23B, RPL27B and RPL32 (Figure 4B), suggesting
that TFIID-abundance is not correlated to HMO1-
abundance or HMO1-dependent recruitment of FHL1.
Intriguingly, taf1TAND weakened transcription of these
RPGs, whereas it enhanced TFIID occupancy at the
promoters, irrespective of whether HMO1 was intact or
not (compare open and dark gray bars in Figure 4B).
These data are in good agreement with previous results
suggesting that TAND is inhibitory for TFIID binding
but necessary for eﬃcient transcription (11,51,58).
hmo1 decreased transcription and TFIID occupancy
at these promoters in TAF1 strains (open bars in
Figure 4B). However, in taf1TAND strains, hmo1
decreased transcription of RPS31, RPL3 and RPL10 but
increased TFIID occupancy at these promoters (dark gray
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Figure 3. The eﬀect of hmo1 on transcription of class II genes.
(A) Transcription of TAND-dependent genes in hmo1 and/or
taf1TAND mutants. Northern blot analysis was used to determine
the expression of PHO84, PHO12, HIS4, RPS5, ACT1 and 25S rRNA
in the indicated strains. Total RNA (20mg) was blotted onto the
membrane and hybridized with the gene-speciﬁc probes indicated at the
left. The raw data (left panel) were quantiﬁed and are presented
graphically in the right panel. Values for each transcript were normal-
ized to the maximum expression of that transcript. (B) Transcription of
an inducible gene in hmo1 and/or taf1TAND mutants. Expression
of GAL1 (inducible) and ACT1 (constitutive, control) was measured by
northern blot analysis in the indicated strains. Cultures were grown in
3% raﬃnose synthetic medium to mid-log phase at 308C, then the same
volume of 4% galactose synthetic medium was added and the cultures
grown for 3h at 308C. Aliquots of the culture were harvested at t=0,
0.5, 1 and 3h (lanes 1–4, respectively) after addition of galactose.
Total RNA was isolated from these samples and then analyzed as
described in A.
1348 Nucleic Acids Research, 2008, Vol. 36, No. 4bars in Figure 4B). These observations imply that HMO1
may facilitate binding of intact TFIID but inhibit that of
TFIIDTAND to these promoters. Given that only three
of the seven RPGs are HMO1-limited and recruit FHL1 in
an HMO1-independent manner (23), HMO1 and TAND/
TFIID may function at each RPG promoter in a class-
speciﬁc manner.
Genetic interaction between HMO1 and
TBP, TFIIB, TFIIA
We investigated the genetic relationship between HMO1
and SPT15 (TBP; Figure 5A), SUA7 (TFIIB; Figure 5B)
and TOA1 (TFIIA; Figure 5C). To construct strains
deﬁcient in SPT15 and/or HMO1, plasmids were shuﬄed
in spt15 and hmo1 spt15 backgrounds. In the
newly constructed strains, a URA3-marker plasmid
expressing SPT15 was replaced with a TRP1-marker
plasmid expressing wild-type or mutant spt15 (39). The
viability of these strains was tested at 308C, 348C and 378C
in rich medium (Figure 5A). The presence of the hmo1
defect altered the growth of some but not all spt15 mutant
strains. The aﬀected strains were spt15-E236P, K239L,
F237D, K138T/Y139A, N159L and P65S, demonstrating
an allele-speciﬁc genetic interactions between HMO1
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Figure 4. In vivo association of TAF1 with RPG promoters. (A) In vivo binding of TAF1 to the promoter region of RPS5, RPS31, RPL10, RPL3,
RPL27B, RPL23B and RPL32 was analyzed using ChIP assays. Yeast strains were grown in YPD medium to mid-log phase at 258C. Cross-linked
chromatin from HMO1 or hmo1 strains expressing TAP-tagged TAF1, with or without the TAF N-terminal domain (TAND; 2–186 aa), as
indicated, was prepared and precipitated with either IgG-Sepharose 6 FastFlow (IgG; +) or Sepharose 6 FastFlow (IgG;  , negative control) beads.
After reversal of cross-linking, PCR was performed to test for the presence of DNA corresponding to the promoter regions of the indicated genes.
Each PCR reaction contained a second primer pair that ampliﬁes a region (218bp) of the POL1 ORF as an internal background control (asterisk)
(27). The lower panel (input) shows the results of PCR conducted with the chromatin prior to precipitation. (B) Quantitation of the raw data shown
in A. Signals corresponding to each band were quantiﬁed by an image analyzer after staining with SYBR Green I. The ratio of the precipitated signal
(IP) to the input signal from each lysate (table at bottom) was calculated for all the indicated RPG promoters (top panel) as well as for the POL1
ORF (middle panel). Northern blot analysis was also conducted as described in Figure 3A. The raw data (data not shown) were quantiﬁed and are
presented graphically in the bottom panel. Values for each transcript were normalized to the maximum expression of that transcript.
Nucleic Acids Research, 2008, Vol. 36, No. 4 1349and TBP. Because ﬁve of six (all except K239L) of the
aﬀected spt15 mutant alleles are deﬁcient in Pol
II-dependent but not Pol I-dependent transcription
(59–63), these results indicate that HMO1 may be more
intimately involved in the TBP-mediated core promoter
function of class II genes than of the 35S rRNA gene.
Consistent with this hypothesis, HMO1 binds speciﬁcally
to the promoter regions of class II genes whereas it binds
more broadly to the entire 35S rRNA gene (22,23). The
allele-speciﬁc interactions between HMO1 and SPT15
suggest a highly speciﬁc interaction between these two
genes/proteins.
TFIIB mutants were also tested for genetic inter-
actions with hmo1 (Figure 5B). Intriguingly, Dhmo1
rescued the growth defects of sua7-K190E (64), K201E
(64) and R78C (65) at 30/358C, 30/35/378C and 378C,
respectively. A similar, but weaker interaction was
observed for sua7-E62K (65) at 378C. These results
indicate that HMO1 and TFIIB have antagonistic roles,
as do HMO1 and TAND (Figures 2B, C and 3A) and
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Figure 5. Genetic interaction between HMO1 and SPT15(TBP), SUA7(TFIIB), TOA1(TFIIA). (A). Eﬀect of hmo1 and spt15 on growth.
The spt15 and spt15 hmo1 strains carrying plasmid encoding SPT15 (WT) or spt15 mutant alleles (indicated at the left) were spotted onto
YPD plates at three dilutions and grown for 5 days at the temperatures indicated. Relative growth rates are indicated at the right. Mutants
marked with an asterisk are deﬁcient in Pol II-dependent but not Pol I-dependent transcription (59–63). (B) Eﬀect of hmo1 and sua7 on growth.
The sua7 and sua7 hmo1 strains carrying plasmid encoding SUA7 (WT) or sua7 mutant alleles were grown as described in A. (C) Eﬀect of
hmo1 and toa1 on growth. The toa1 and toa1 hmo1 strains carrying plasmid encoding TOA1 (WT) or toa1 mutant alleles were grown as
described in A.
1350 Nucleic Acids Research, 2008, Vol. 36, No. 4that HMO1 may compete with TFIIB and TAND for
binding to TBP.
Similar analyses were performed for several TFIIA
mutants (Figure 5C). The results indicate a genetic
interaction between hmo1 and toa1-(55–215) (66)
(35/378C), toa1-K255A/R257A/K259A (67) (35/378C) and
toa1-W285A (68) (378C). In summary, these results
indicate that HMO1 may regulate transcription of class
II genes by aﬀecting the formation and/or stability of the
TFIIA–TFIIB–TBP/TFIID–promoter complex.
"hmo1restores transcription ofclass II genesin several
sua7 mutants
The results described above showed that hmo1 reduces
the growth of some spt15 and toa1 mutants (Figure 5A
and C), while it restores the growth of some sua7
mutants (Figure 5B). Thus, we asked whether the
eﬀect of hmo1 on transcription of class II genes is
consistent with these growth phenotypes. Indeed, hmo1
impairs transcription of some genes in the spt15 and toa1
mutants whereas it restores transcription in the sua7
mutants.
Northern blot analysis was conducted for the strains
described above (Figure 5). The results show that hmo1
signiﬁcantly reduced the expression of HIS4 at 258C
and 378C in the spt15-E236P and -K239L mutants
(Supplementary Figure 1A). A similar but weaker eﬀect
of hmo1 was observed in the spt15-F237D and -N159L
mutants (Supplementary Figure 1A). In contrast, the
spt15-K138T/Y139A mutation almost completely abol-
ished HIS4 expression at both temperatures even in the
HMO1 strain (Supplementary Figure 1A). Such a detri-
mental eﬀect of hmo1 in the spt15 mutants seems to be
speciﬁc for a subset of genes since it was observed for
HIS4 but not for TEF2 (Supplementary Figure 1A), even
though HMO1 binds to both promoters at similar levels
(23). These results indicate that HMO1 plays diﬀerent
roles in transcription at diﬀerent promoters.
Consistent with the growth phenotypes, hmo1 restored
the expression of RPS5 at 258C and 378C in the sua7-
K190E and -K201E mutants (Supplementary Figure 1B).
A similar but much weaker eﬀect of hmo1 was observed
in the sua7-E62K and -R78C mutants (Supplementary
Figure 1B). Furthermore, hmo1 restored the expression
of HIS4 in the sua7-K190E (378C), -K201E (378C), -E62K
(25/378C) and -R78C (25/378C) mutants (Supplementary
Figure 1B). hmo1 also restored the expression of TEF2
in the sua7-K190E and -K201E mutants (25/378C)
(Supplementary Figure 1B). Previous studies have shown
that the sua7-K190E and -K201E mutations are defective in
forming a stable TFIIB–TBP–DNA complex while sua7-
E62K and -R78C mutations shift the transcriptional start
site downstream (64,65). Therefore, these results indicate
that HMO1 could restore a range of transcriptional defects
caused by diﬀerent types of sua7 mutations.
Finally, northern blot analyses showed that hmo1
signiﬁcantly reduced expression of HIS4 (25/378C) and
RPS5/TEF2 (25/378C) in the toa1-D(55–215) and toa1-
W285A mutants, respectively (Supplementary Figure 1B).
Thus, we conclude that the eﬀects of hmo1 on growth
and on transcription of a subset of class II genes are well
correlated in several spt15, sua7 and toa1 mutants.
HMO1 participates in startsite selection of asubsetof
class IIgenes
The results described above indicate that HMO1 and
TFIIB function antagonistically in growth and transcrip-
tion. Since some TFIIB mutants like sua7-E62K and -
R78C cause a downstream shift in transcriptional start site
(64,65), we examined whether hmo1 caused an upstream
shift, i.e. a shift in the opposite direction. Transcriptional
start sites of RPS5, RPL32, RPS31 and RPL10 were
examined by primer extension analysis in some of the
strains described in Figure 5B (Figure 6A–D). The
electrophoretic images were scanned and quantiﬁed to
compare the positions of transcriptional start sites
(Figure 6E–H). The sua7-R78C but not the sua7-K190E
mutant shifted transcriptional start site of these four genes
slightly downstream (compare lanes 1, 3 and 5 in
Figure 6A–D), whereas hmo1 alone shifted the tran-
scriptional start site of RPS5 and RPL32, but not of
RPS31 and RPL10, upstream (compare lanes 1 and 2 in
Figure 6A–D). These results indicate that HMO1 parti-
cipates in start site selection of a subset of genes. Indeed, a
similar upstream shift in transcriptional start site was
observed for RPS16A, RPL23B and RPL27B, but not for
TEF2 and ADH1 (data not shown, Supplementary
Figure 2). Notably, hmo1 also shifted the transcriptional
start sites of the same set of genes, i.e. RPS5, RPS16A,
RPL23B, RPL27B and RPL32, upstream in the sua7-
R78C mutant, and less strongly than in the SUA7 strain
(Figure 6A and B, data not shown). In contrast, the
upstream shift in transcriptional start sites of these genes
induced by hmo1 was quite weak or almost undetectable
in the sua7-K190E strain (Figure 6A and B, data not
shown). Similar results were obtained when the experi-
ments were conducted at diﬀerent temperatures (i.e. 308C,
358C and 378C) (Supplementary Figure 2, data not
shown).
These observations could explain, at least in part, how
hmo1 restored the growth of the sua7-R78C mutant at
378C (Figure 5B). Furthermore, given that hmo1 cannot
cause a strong upstream shift in the sua7-K190E mutant,
stable TFIIB–TBP–DNA complex formation must be
important for transcriptional initiation from upstream
regions. HMO1 is enriched at the promoters of RPS5,
RPS16A, RPL23B, RPL27B and RPL32 but limited
at those of RPS31, RPL10, TEF2 and ADH1 (23).
Therefore, HMO1 may play more direct and important
roles in start site selection at HMO1-enriched promoters
than at HMO1-limited promoters.
DISCUSSION
In this study, we identiﬁed HMO1 as a TAND-interacting
protein using the Sos recruitment system (Figure 1A) and
showed that HMO1 binds directly to TBP and TFIID
(Figure 1B and C). Our evidence suggests that HMO1
may function with TAND either antagonistically or
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Figure 6. The eﬀect of hmo1 on start site selection of class II genes in sua7 mutants. (A) Transcriptional start sites of RPS5 in hmo1 and/or sua7
mutants. Total RNA (20mg) from strains containing the alleles indicated at the top was isolated 2h after a temperature shift to 378C from 308C
before being subjected to primer extension analysis. The position of a major transcriptional start site (C at  37 numbered relative to the A (+1) of
the start codon ATG) is indicated by the asterisk. (B). Transcriptional start sites of RPL32 in hmo1 and/or sua7 mutants. Primer extension analysis
was done as described in A. A major transcriptional start site at  365 is indicated by the asterisk. (C) Transcriptional start sites of RPS31 in hmo1
and/or sua7 mutants. Primer extension analysis was done as described in A. A major transcriptional start site at  57 is indicated by the asterisk. (D)
Transcriptional start sites of RPL10 in hmo1 and/or sua7 mutants. Primer extension analysis was done as described in A. A major transcriptional
start site at  21 is indicated by the asterisk. (E) Each lane of the electropherogram shown in A was scanned and quantiﬁed by densitometry (Multi
Gauge ver.3.0, Fuji Film) (SUA7, left panel; sua7-R78C, center panel; sua7-K190E, right panel). The solid and broken lines represent the results
obtained from HMO1 and hmo1 strains, respectively. Asterisks indicate the peaks that correspond to the major transcriptional start sites described
in A. The upstream regions were expanded and are shown in the lower panels to make the diﬀerences between HMO1 and hmo1 strains more
evident. (F) Each lane of the electropherogram shown in B was scanned and presented as described in E. (G) Each lane of the electropherogram
shown in C was scanned and presented as described in E. (H) Each lane of the electropherogram shown in D was scanned and presented as
described in E.
1352 Nucleic Acids Research, 2008, Vol. 36, No. 4cooperatively in supporting cell growth (Figure 2) and
transcription of a subset of class II genes (Figure 3).
Furthermore, allele-speciﬁc interactions of hmo1 with
spt15, sua7 and toa1 indicate that HMO1 may be involved
in TFIIA–TFIIB–TBP/TFIID–DNA complex formation
(Figure 5, Supplementary Figure 1).
NHP6A/B, another well-characterized HMGB
protein in yeast, may also enhance assembly of the
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Nucleic Acids Research, 2008, Vol. 36, No. 4 1353TFIIA–TBP–DNA complex (20,69). Does NHP6A/B play
a role similar to HMO1 in transcription? Substitutions
of TBP residues F237/K239, K138/Y139 or P65 exhibited
synthetic growth defects in hmo1 cells (Figure 5A).
Similarly, these substitutions were lethal in nhp6a/b cells
(70). However, hmo1 exhibited no apparent synthetic
phenotype with nhp6a/b (57). These results suggest that
HMO1 and NHP6A/B are not functionally redundant,
but that they may instead have complementary functions,
for example, in regulating diﬀerent subsets of class II genes
via similar mechanisms. In fact, each plays a crucial role
in Pol I (21) and Pol III (71) transcription, respectively.
hmo1 caused growth defects in some, but not all, of
the TBP mutants that are lethal with taf1TAND. For
instance, the TBP mutations N159D, V161A and S118L
have growth defects in combination with taf1TAND
(39), but not with hmo1 (Figure 5A). These observations
indicate that HMO1 and TAND have both shared and
unique functional roles, which is consistent with the
observation that the synthetic defect between taf1TAND
and hmo1 is relatively weak (Figure 2A).
One of the most intriguing ﬁndings of this study is that
hmo1 causes an upstream shift in transcriptional start
sites of a subset of genes (Figure 6, data not shown). This
phenotype is uncommon and has previously been found in
mutations of four polypeptides within the preinitiation
complex (PIC), i.e. the TFG1 and TFG2 subunits of
TFIIF (31–33) and the RPB2 and RPB9 subunits of Pol II
(34–37). Conversely, mutations in the amino-terminal
B-ﬁnger region (e.g. residues E62, F63, R64, F66, R78 and
V79) of TFIIB (64,65,72) and in the RPB1 subunit (e.g.
residues K332, R344 and N445 in the active site) of Pol II
(73,74) cause a downstream shift in transcriptional start
site. Mutations of TFG1, TFG2, RPB2 and RPB9 could
rescue growth defects and suppress the downstream start
site shift caused by mutations of SUA7 (TFIIB) and
RPB1. Similarly, our current study showed that hmo1
could rescue the growth and transcriptional defects of
some TFIIB mutants (Figures 5 and 6, and Supplementary
Figure 1). Thus, it will be important in future studies to
determine whether hmo1 and mutations of TFIIF/Pol II
cause upstream start site shifts by similar or diﬀerent
mechanisms.
The dimerization domain (i.e. the interface between
TFG1 and TFG2) of TFIIF and the B-ﬁnger of TFIIB lie
within the active site of Pol II in the PIC (32,74,75). In
contrast, the position of the G369 residue of RPB2, whose
mutation causes an upstream start site shift and sup-
presses the growth and transcriptional defects of the
TFIIB mutant, was located near RPB9 but distal to the
active site of Pol II (76). However, mutations of RPB2 and
RPB9 may impair interactions between TFIIF and Pol II
(33). Furthermore, a mutation in the switch 2 region of
Pol II (i.e. rpb1-R344A) that causes a downstream start
site shift destabilizes a short RNA–DNA hybrid in the
active site and thereby increases the frequency of abortive
initiation (74). Based on these and other observations, an
intriguing model was recently proposed for the roles
G
H
SUA7 sua7 [R78C] sua7 [K190E]
SUA7 sua7 [R78C] sua7 [K190E]
*
*
*
*
**
RPS31
RPL10
8000
7000
6000
5000
4000
3000
2000
1000
3000
2500
2000
1500
1000
500
0
3000
2500
2000
1500
1000
500
0
3000
2500
2000
1500
1000
500
0
0
0 50 100 150 200 250
0 50 100 150 200 250 300 0 50 100 150 200 250 300 0 50 100 150 200 250 300
0 50 100 150 200 250 0 50 100 150 200 250
8000
7000
6000
5000
4000
3000
2000
1000
0
8000
7000
6000
5000
4000
3000
2000
1000
0
Figure 6. Continued.
1354 Nucleic Acids Research, 2008, Vol. 36, No. 4played by the B-ﬁnger of TFIIB, TFIIF and the switch 2
region of Pol II (74). In this model, the nascent short
RNA–DNA hybrid is initially stabilized by the B-ﬁnger of
TFIIB, and continued synthesis of RNA induces a
conformational change in Pol II, presumably mediated
by TFIIF. Subsequently, the switch 2 region is reposi-
tioned in the active site to displace the B-ﬁnger and then
stabilize the 30-end of the RNA–DNA hybrid. Thus,
mutations of the B-ﬁnger and switch 2 region that fail to
stabilize the RNA–DNA hybrid in the active site would
increase the frequency of abortive initiations and result in
re-initiation from sites farther downstream. Mutations of
TFIIF and Pol II that disrupt the appropriate TFIIF–Pol
II interactions may generate an initiation complex that
more readily undergoes the conformational change to
start transcription from sites farther upstream than
normal.
One possible explanation for the phenotypes of hmo1
is that the absence of HMO1 disrupts the appropriate
TFIIF–Pol II interactions indirectly, as proposed for
RPB2 and RPB9 mutants. However, HMO1 may be
involved in TFIIA–TFIIB–TBP/TFIID–DNA complex
formation, as described above. In addition, the ADH1
transcriptional start site was shifted in TFIIB, TFIIF, and
Pol II mutants, but not in the hmo1 mutant
(Supplementary Figure 2). Thus, the alternative hypoth-
esis that the absence of HMO1 may facilitate TFIIA–
TFIIB–TBP/TFIID–DNA complex formation at sites
farther upstream than normal should be considered. In
this regard, it is notable that TBP (SPT15) and several
components of SAGA, e.g. SPT3, SPT7, SPT8 and
SPT20, were originally isolated as SPT genes that
suppress Spt- phenotypes, indicating that mutations in
TBP or SAGA weakened transcription of the transposon
Ty or d element, but enhanced transcription of adjacent
genes (77,78). Although the precise mechanisms by which
these mutations could induce a promoter shift from the
transposon to an adjacent gene remain unknown, it is
likely that TBP binding may be altered to prefer the latter
promoter. Hence, it is also possible that hmo1 may alter
the site of TBP binding upstream by similar mechanisms.
Recently, NHP6A/B was shown to serve as a Pol III
initiation ﬁdelity factor, since nhp6a/b cells lose initia-
tion ﬁdelity (i.e. generate many ectopic initiation sites) at
some, but not all, tRNA genes (79). Biochemical analyses
suggest that NHP6A/B may directly promote accurate
binding of TFIIIB to the correct position, or indirectly via
the function of TFIIIC. Although HMO1 does not show
similar activity in the Pol III system (79), it may play an
analogous role in the Pol II system, e.g. by promoting
correct binding of TBP/TFIID at a subset of class II gene
promoters.
The functions of HMO1 and NHP6A/B in start site
selection appear to be promoter-speciﬁc (Figure 6,
Supplementary Figure 2, data not shown) (79). Notably,
the eﬀects of TFIIB and Pol II mutations are also
promoter-speciﬁc; they shifted transcriptional start sites
of ADH1 and CYC1 but not of HIS3 (72,73). Mutation
analyses using ADH1–HIS3 hybrid promoters revealed
that the feature that confers sensitivity to TFIIB muta-
tions is encoded in the sequence surrounding the start site
and not by the spacing between the TATA element and
the start site (72). Similar but more intricate promoter-
speciﬁc eﬀects were observed for a E51 mutation
(corresponding to E62 in yeast) within the B-ﬁnger of
human TFIIB; this mutation shifted the transcriptional
start site of the AdE4 promoter downstream and that of
HIV-LTR upstream, even though it did not aﬀect the
transcriptional start sites of AdML and hIGFII promoters
(80). Consistent with yeast studies, hybrid promoter
analysis showed that these promoter-speciﬁc eﬀects were
determined by the sequence surrounding the start site
(i.e. initiator) (80). Intriguingly, the same mutation shifted
transcriptional start site of HIV-LTR downstream (i.e. in
the opposite direction) when a single base-pair substitu-
tion was introduced at a speciﬁc position in the initiator
region of this promoter (80). These observations indicate a
common mechanism of TFIIB-mediated start site selec-
tion that is conserved from yeast to human, although the
identity of the human counterpart of HMO1 still remains
unclear (21–23).
Our previous study showed that HMO1-abundance
and HMO1-dependence of transcription and FHL1-
recruitment were determined by the promoter sequence
itself, at least in the case of RPS5 and RPL10 (23). Thus,
the promoter sequence may also determine the sensitivity
of start site selection to hmo1. Further studies are
required to elucidate the full role played by HMO1 in
transcription, and, particularly, in start site selection
in RPGs and other HMO1-dependent class II genes.
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